Biomedical subjects

Maria Fernanda Mendes

Publications and source records attributed to Maria Fernanda Mendes.

5 recordsLinked to original sources

PubMed2006

[Fatigability evaluation on multiple sclerosis patients by using a hand held dynamometer].

Fatigue is one of the most common disabling symptoms in multiple sclerosis (MS). The aim of this study was to evaluate the fatigability on patients with MS by the application of hand grip isotonic and isometric exercises with dynamometer. As results the fatigability, the isometric strength and time were statistically similar in the control group and in MS. We conclude that although fatigue is a frequent subjective complaint on MS, the fatigability and the recover after exercises seems to be normal.

Adult↗

PubMed2006

Immunomodulatory treatment in multiple sclerosis: experience at a Brazilian center with 390 patients.

UNLABELLED: Since 1993 the Federal Drug Administration approved the use of immunomodulatory therapy in multiple sclerosis (MS), modifying the natural course of disease, as demonstrate our experience in treatment of MS patients at the MS Treatment Center (CATEM). OBJECTIVE: To evaluate patient behavior using immunomodulatory therapy for a period of five years treatment. METHOD: We selected 390 patients in CATEM with relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS) with relapses. RESULTS: At initial treatment 292 (61.5%) patients presented RRMS, 98 (20.6%) SPMS with relapses, 27 SPMS (5.6%) and 58 (12.1%) primary progressive MS (PPMS). In RRMS 182 (62.5%) used the interferon beta 1a SC, 15 (5.2%) interferon beta 1a IM, 85 (29%) interferon beta 1b and 10 (3.3%) glatiramer acetate. In SPMS 63 (64.3%) used interferon beta 1a SC, 4 (4.1%) interferon beta 1a IM and 31 (31.4%) interferon beta 1b. We observed that in this period 195 (50%) migrated between drugs, 35 (9%) gave up therapy and 160 (41%) continued the initial therapy. CONCLUSION: Stopping the immunomodulatory therapy emerges as a problem in the second year of treatment and it can be a subset of interferon non responsive or development of neutralizing antibodies.

Adjuvants, Immunologic↗

PubMed2005

[Multiple Sclerosis Functional Composite Measure (MSFC) standardized in the Brazilian population].

The Multiple Sclerosis Functional Composite Measure (MSFC) is an outcome measure in multiple sclerosis developed by USA National Multiple Sclerosis Society (1994), a three-part composite clinical measure--9-Hole Peg Test, Timed 25-Foot Walk and PASAT. It should be multidimensional in order to reflect the principal ways MS affects an individual. The MSFC was applied in 91 Brazilian subjects and standardized to be use in MS centers.

Adult↗

PubMed2004

[Validation of the functional assessment of multiple sclerosis quality of life instrument in a Portuguese language].

The objective of the present study was to translate, to do cultural equivalence and validation of the Functional Assessment of Multiple Sclerosis quality of life instrument (FAMS) to Portuguese. The database analyzed is longitudinal, with 143 patients with clinically defined multiple sclerosis (MS). The validity of the scale was established by correlating total FAMS scores and sub-scales scores to EDSS and EAN. The internal consistency reliability were similar to those of the original FAMS. All sub-scales correlated with each other (0.35 to 0.71). Total FAMS score correlated significantly with EDSS, and EAN. All sub-scales correlated to EDSS. Kendall's Tau coefficient, showed significant associations between basal and first visit. Responsiveness was investigated considering two groups: patients with EDSS < 3.5 and with EDSS > 3.5. There was significantly higher score in the group with light EDSS when compared to the group of patients with moderate EDSS. One can conclude, based on this retrospective study that FAMS instrument translated to Brazilian Portuguese can be considered reliable, responsive and content valid.

Disability Evaluation↗

PubMed2003

[Depression in relapsing-remitting multiple sclerosis].

The suggestion of a possible relationship between depression and multiple sclerosis (MS) has existed for many years, and the prevalence studies are believed by potential biases. In our country, the prevalence of clinical depression in patients with MS is unknown. The objective of the present study was to ascertain the rate of depression in a group of MS patients and to analyze the relationship to depression, disability, gender, age and duration of illness. We evaluated 84 relapsing-remitting MS patients using the Beck Scale (BS), the Hospital Anxiety and Depression scale (HAD) and the Expanded Disability Status Scale (EDSS). The depression was presented at 17.9% and the anxiety at 34.5% of the RRMS patients. There is a correlation between depression and functional disability (p=0.0002), but there is no relation between depression and sex, age or duration of the illness. This analysis confirms that depression is common in persons with MS and suggests the association with functional disability.

Adolescent↗